Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Mol Genet Genomic Med ; 7(11): e972, 2019 11.
Article in English | MEDLINE | ID: mdl-31566936

ABSTRACT

BACKGROUND: Rubinstein-Taybi syndrome (RSTS) is a rare congenital disorder characterized by broad thumbs and halluces, intellectual disability, distinctive facial features, and growth retardation. Clinical manifestations of RSTS are varied and overlap with other syndromes' phenotype, which makes clinical diagnosis challenging. CREBBP is the major causative gene (55%-60% of the cases), whereas pathogenic variants found in EP300 represent the molecular cause in 8% of RSTS patients. A wide range of CREBBP pathogenic variants have been reported so far, including point mutations (30%-50%) and large deletions (10%). METHODS: The aim of this study was to characterize the CREBBP genetic variant spectrum in 39 RSTS patients using Multiplex Ligation-dependent Probe Amplification and DNA sequencing techniques (Sanger and Trio-based whole-exome sequencing). RESULTS: We identified 15 intragenic deletions/duplications, ranging from one exon to the entire gene. As a whole, 25 de novo point variants were detected: 4 missense, 12 nonsense, 5 frameshift, and 4 splicing pathogenic variants. Three of them were classified as of uncertain significance and one of the patients carried two different variants. CONCLUSION: Seventeen of the 40 genetic variants detected were reported for the first time in this work contributing, thus, to expand the molecular knowledge of this complex disorder.


Subject(s)
CREB-Binding Protein/genetics , E1A-Associated p300 Protein/genetics , Genetic Association Studies , Mutation , Rubinstein-Taybi Syndrome/genetics , Rubinstein-Taybi Syndrome/pathology , Adolescent , Adult , Child , Child, Preschool , Female , Genotype , Humans , Infant , Male , Phenotype , Young Adult
2.
J Neurol Sci ; 344(1-2): 37-42, 2014 Sep 15.
Article in English | MEDLINE | ID: mdl-24996492

ABSTRACT

Alternating hemiplegia of childhood (AHC) is a rare neurodevelopmental disorder featuring attacks of hemiplegia and other paroxysmal and non-paroxysmal manifestations leading to progressive neurological impairment. De novo mutations in ATP1A3 have been identified in up to 80% of patients. AHC is also associated with rare mutations in other genes involved in episodic neurological disorders. We sought to find mutations in ATP1A3, CACNA1A, ATP1A2, SCN1A and SLC2A1 in a cohort of ten unrelated patients from Spain and Greece. All patients fulfilled AHC diagnostic criteria. All five genes were amplified by PCR and Sanger sequenced. Copy number variation (CNV) analysis of SLC2A1 and CACNA1A was performed using two different approaches. We identified three previously described heterozygous missense ATP1A3 mutations (p.Asp801Asn, p.Glu815Lys and p.Gly947Arg) in five patients. No disease-causing mutations were found in the remaining genes. All mutations occurred de novo; carriers presented on average earlier than non-carriers. Intellectual disability was more severe with the p.Glu815Lys variant. A p.Gly947Arg carrier harbored a maternally-inherited CACNA1A p.Ala454Thr variant. Of note, three of our patients exhibited remarkable clinical responses to the ketogenic diet. We confirmed ATP1A3 mutations in half of our patients. Further AHC genetic studies will need to investigate large rearrangements in ATP1A3 or consider greater genetic heterogeneity than previously suspected.


Subject(s)
DNA Copy Number Variations/genetics , Diet, Ketogenic/methods , Hemiplegia/diet therapy , Hemiplegia/genetics , Sodium-Potassium-Exchanging ATPase/genetics , Adolescent , Child , DNA Mutational Analysis , Europe/epidemiology , Female , Greece , Humans , Male , Models, Molecular
3.
Rev. neurol. (Ed. impr.) ; 54(9): 544-550, 1 mayo, 2012. ilus, tab
Article in Spanish | IBECS | ID: ibc-99990

ABSTRACT

Introducción. Las lipofuscinosis neuronales ceroideas (LNC) se clasifican, según la edad de inicio de la sintomatología, en cuatro formas clínicas principales en la infancia: infantil, infantil tardía, juvenil y congénita (CLN1, CLN2, CLN3 y CLN10).Las formas variantes infantiles tardías (CLN5, CLN6, CLN7 y CLN8) se caracterizan por una gran variabilidad fenotípica y la mayoría de los pacientes proceden de Finlandia y Turquía (variante finlandesa, CLN5, y turca, CLN7). Casos clínicos. Se describen tres pacientes con la variante finlandesa y un cuarto paciente con la variante turca, procedentes de diferentes familias. Se propone un algoritmo que facilite el diagnóstico de este grupo de enfermedades poco prevalentes. Las pacientes con la variante finlandesa iniciaron un trastorno de conducta entre los 2,6 y 4,6 años seguido de dificultades de aprendizaje y déficit visual a los 6 años de edad. Las crisis epilépticas generalizadas y mioclonoatónicas aparecieron a los 7 años con sacudidas mioclónicas posteriormente. Las pacientes desarrollaron ataxia y ceguera a los 9años, y manifestaron una importante discapacidad a los 11 años de edad. El paciente con la variante turca presentó epilepsia refractaria desde los 2 años de edad seguido de un rápido deterioro con ataxia, pérdida de la deambulación en los dos a tres años siguientes y estado vegetativo a los 11 años.Conclusiones. El espectro de las formas variantes de LNC presenta una distribución geográfica cada vez más amplia. Nuestro estudio aporta tres nuevas mutaciones en el gen CLN5 y propone un protocolo de diagnóstico que facilite los estudios de correlación genotipo-fenotipo (AU)


Introduction. The neuronal ceroid lipofuscinosis are classified based on age at onset into four main clinical forms in childhood: infantile, late infantile, juvenile and congenital (CLN1, CLN2, CLN3 and CLN10). The variant late infantile forms (CLN5, CLN6, CLN7 and CLN8) are characterized by a wide variability of the clinical phenotypes and the most patients are originated from Finland and Turkey (Finnish, CLN5, and Turkish, CLN7 variants). Case reports. We describe three unrelated patients with Finnish variant and another patient with Turkish variant. We describe an algorithm to facility the diagnosis of these low prevalence diseases. Patients with Finnish variant started withbehaviour disorder between 2.6 and 4.6 years of age followed by learning difficulties and visual failure at an age of 6 years. Generalised tonic-clonic and myoclonic seizures were observed at 7 years of age with myoclonic jerks later on. Patients developed ataxia and blindness within 9 years and increasingly disability at 11 years of age. The patient with Turkish variant started with refractory epilepsy at age of 2, followed by a severe neurodegeneration manifested by ataxia,loss of walking ability within 2-3 years and vegetative state at 11 years of age.Conclusions. The clinical spectrum of the variant late infantile forms shows a wide geographical distribution. We report three novel mutations in the CLN5 gene and a diagnostic algorithm to facility the correlation genotype-phenotype studies (AU)


Subject(s)
Humans , Female , Child , Neuronal Ceroid-Lipofuscinoses/diagnosis , Algorithms , Neuronal Ceroid-Lipofuscinoses/classification , Genotype , Phenotype , Learning Disabilities/etiology , Child Behavior Disorders/etiology
4.
Rev Neurol ; 54(9): 544-50, 2012 May 01.
Article in Spanish | MEDLINE | ID: mdl-22532218

ABSTRACT

INTRODUCTION: The neuronal ceroid lipofuscinosis are classified based on age at onset into four main clinical forms in child-hood: infantile, late infantile, juvenile and congenital (CLN1, CLN2, CLN3 and CLN10). The variant late infantile forms (CLN5, CLN6, CLN7 and CLN8) are characterized by a wide variability of the clinical phenotypes and the most patients are originated from Finland and Turkey (Finnish, CLN5, and Turkish, CLN7 variants). CASE REPORTS: We describe three unrelated patients with Finnish variant and another patient with Turkish variant. We describe an algorithm to facility the diagnosis of these low prevalence diseases. Patients with Finnish variant started with behaviour disorder between 2.6 and 4.6 years of age followed by learning difficulties and visual failure at an age of 6 years. Generalised tonic-clonic and myoclonic seizures were observed at 7 years of age with myoclonic jerks later on. Patients developed ataxia and blindness within 9 years and increasingly disability at 11 years of age. The patient with Turkish variant started with refractory epilepsy at age of 2, followed by a severe neurodegeneration manifested by ataxia, loss of walking ability within 2-3 years and vegetative state at 11 years of age. CONCLUSIONS: The clinical spectrum of the variant late infantile forms shows a wide geographical distribution. We report three novel mutations in the CLN5 gene and a diagnostic algorithm to facility the correlation genotype-phenotype studies.


Subject(s)
Algorithms , Neuronal Ceroid-Lipofuscinoses/diagnosis , Child , Child, Preschool , Female , Finland , Humans , Male , Neuronal Ceroid-Lipofuscinoses/classification , Tripeptidyl-Peptidase 1 , Turkey
5.
Gene ; 499(2): 297-302, 2012 May 15.
Article in English | MEDLINE | ID: mdl-22387303

ABSTRACT

Infantile neuronal ceroid lipofuscinosis (INCL; NCL1, Haltia-Santavuori disease) is caused by mutations in the CLN1/PPT gene which are associated with an early onset INCL phenotype. The most detailed descriptions of INCL have come from Finland and a few series have been reported from southern European countries. Clinical course and follow-up of six Spanish patients with INCL are reported with the aim of assessing the chronological evolution and severity of this disease. The age at disease onset ranged from 8 to 15 months. Delayed motor skills were the initial symptom when the disease began before 12 months of age, and ataxia was the first sign when the disease began later. Cognitive decline, which is described between 12 and 18 months of age, occurred from 16 to 20 months of age. In our series early stage is characterized by motor impairment, cognitive decline and autistic features. Visual failure may appear simultaneously with the neurological symptoms, leading quickly to blindness. As reported, psychomotor regression appeared between 2 and 3 years of age. Myoclonic jerks occurred after 24 months of age and epilepsy was the last symptom of the disease. We report two novel mutations in a patient without epilepsy to date and describe the features of two siblings homozygous for the V181M (c.541G>A) mutation, associated with the most severe INCL phenotype. The clinical evolution might be helpful to identify patients affected by this rare disease. Early diagnosis is essential in order to provide genetic counselling to affected families. Our series may contribute to the study of the genotype-phenotype INCL correlation in the Mediterranean countries.


Subject(s)
Neuronal Ceroid-Lipofuscinoses/genetics , Neuronal Ceroid-Lipofuscinoses/physiopathology , Brain/pathology , Child , Child, Preschool , DNA Mutational Analysis , Female , Follow-Up Studies , Humans , Male , Neuronal Ceroid-Lipofuscinoses/diagnosis , Neuronal Ceroid-Lipofuscinoses/pathology , Thiolester Hydrolases/genetics
6.
J Inherit Metab Dis ; 34(5): 1083-93, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21499717

ABSTRACT

BACKGROUND: Juvenile neuronal ceroid lipofuscinosis (JNCL, NCL3, Batten disease) is usually caused by a 1.02-kb deletion in the CLN3 gene. Mutations in the CLN1 gene may be associated with a variant form of JNCL (vJNCL). We report the clinical course and molecular studies in 24 patients with JNCL collected from 1975 to 2010 with the aim of assessing the natural history of the disorder and phenotype/genotype correlations. PATIENTS AND METHODS: Patients were classified into the groups of vJNCL with mutations in the CLN1 gene and/or granular osmiophilic deposit (GROD) inclusion bodies (n = 11) and classic JNCL (cJNCL) with mutations in the CLN3 gene and/or fingerprint (FP) profiles (n = 13). Psychomotor impairment included regression of acquired skills, cognitive decline, and clinical manifestations of the disease. We used Kaplan-Meier analyses to estimate the age of onset of psychomotor impairment. RESULTS: Patients with vJNCL showed learning delay at an earlier age (median 4 years, 95% confidence interval [CI] 3.1-4.8) than those in the cJNCL group (median 8 years, 95% CI 6.2-9.7) (P = 0.001) and regression of acquired skills at a younger age. Patients with vJNCL showed a more severe and progressive clinical course than those with cJNCL. There may be a Gypsy ancestry for V181L missense mutation in the CLN1 gene. CONCLUSIONS: The rate of disease progression may be useful to diagnose vJNCL or cJNCL, which should be confirmed by molecular studies in CLN1/CLN3 genes. Further studies of genotype/phenotype correlation will be helpful for understanding the pathogenesis of this disease.


Subject(s)
Neuronal Ceroid-Lipofuscinoses/genetics , Neuronal Ceroid-Lipofuscinoses/pathology , Adolescent , Adult , Child , Cognition/physiology , DNA Mutational Analysis , Disease Progression , Female , Genetics, Population , Humans , Male , Mental Disorders/epidemiology , Mental Disorders/etiology , Molecular Diagnostic Techniques , Neuronal Ceroid-Lipofuscinoses/epidemiology , Neuronal Ceroid-Lipofuscinoses/physiopathology , Phenotype , Spain/epidemiology , Young Adult
7.
Epileptic Disord ; 13(4): 389-93, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22258043

ABSTRACT

Reflex seizures are a rare phenomenon among epileptic patients, in which an epileptic discharge is triggered by various kinds of stimuli (visual, auditory, tactile or gustatory). Epilepsy is common in Rett syndrome patients (up to 70%), but to the authors' knowledge, no pressure or eating-triggered seizures have yet been reported in Rett children. We describe three epileptic Rett patients with reflex seizures, triggered by food intake or proprioception. One patient with congenital Rett Sd. developed infantile epileptic spasms at around seven months and two patients with classic Rett Sd. presented with generalised tonic-clonic seizures at around five years. Reflex seizures appeared when the patients were teenagers. The congenital-Rett patient presented eating-triggered seizures at the beginning of almost every meal, demonstrated by EEG recording. Both classic Rett patients showed self-provoked pressure -triggered attacks, influenced by stress or excitement. Non-triggered seizures were controlled with carbamazepine or valproate, but reflex seizures did not respond to antiepileptic drugs. Risperidone partially improved self-provoked seizures. When reflex seizures are suspected, reproducing the trigger during EEG recording is fundamental; however, self-provoked seizures depend largely on the patient's will. Optimal therapy (though not always possible) consists of avoiding the trigger. Stress modifiers such as risperidone may help control self-provoked seizures.


Subject(s)
Epilepsy, Reflex/etiology , Rett Syndrome/complications , Adolescent , Anticonvulsants/therapeutic use , Eating/physiology , Electroencephalography , Epilepsy, Reflex/therapy , Female , Forkhead Transcription Factors/genetics , Humans , Methyl-CpG-Binding Protein 2/genetics , Nerve Tissue Proteins/genetics , Proprioception/physiology , Protein Serine-Threonine Kinases/genetics , Rett Syndrome/genetics , Seizures/etiology , Seizures/physiopathology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...